Tempest Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 08/15/22
Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus ConferenceGlobeNewsWire • 07/07/22
Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual MeetingGlobeNewsWire • 05/26/22
Tempest Reports First Quarter 2022 Financial Results and Provides Corporate HighlightsGlobeNewsWire • 05/13/22
Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual MeetingGlobeNewsWire • 04/27/22
Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual MeetingGlobeNewsWire • 04/08/22
Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/08/22
Tempest Announces First Patient Dosed with TPST-1495 in Combination with PembrolizumabGlobeNewsWire • 11/18/21
Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual MeetingGlobeNewsWire • 10/01/21
Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate HighlightsGlobeNewsWire • 08/12/21
H.C. Wainwright Says Targeted Oncology Therapies "Gives An Edge" To Tempest TherapeuticsBenzinga • 07/13/21
TPST Stock: 13 Things to Know About Tempest Therapeutics as Shares Skyrocket Post-MergerInvestorPlace • 07/12/21
Tempest Announces Appointment of Christine Pellizzari to its Board of DirectorsGlobeNewsWire • 07/01/21